CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions

Enrique Álvarez(Washington University in St. Louis), Laura Piccio(Washington University in St. Louis), Robert Mikesell(Washington University in St. Louis), Eric C. Klawiter(Harvard University), Becky Parks(Washington University in St. Louis), Robert T. Naismith(Washington University in St. Louis), Anne H. Cross(Washington University in St. Louis)
Multiple Sclerosis Journal
January 15, 2013
Cited by 127Open Access
Full Text

Abstract

CXCL13, a B-cell chemokine, has been proposed as a biomarker in a variety of conditions, some of which can mimic multiple sclerosis and can have very high levels. In this case-control study, cerebrospinal fluid (CSF) CXCL13 was elevated in multiple sclerosis, neuromyelitis optica and other inflammatory neurological controls compared with noninflammatory controls. Levels did not differentiate disease groups. For all subjects taken together, CSF CXCL13 correlated with CSF WBC, oligoclonal band numbers, CSF protein, EDSS, and neurofilament levels. In subgroup analyses, CSF CXCL13 correlated with CSF WBC in neuromyelitis optica and IgG index in multiple sclerosis. Additionally, serum CXCL13 was elevated in neuromyelitis optica.


Related Papers

No related papers found

Powered by citation graph analysis